Shanghai Henlius Biotech, Inc. Class H · HKEX:2696
Shanghai Henlius Biotech, Inc. Class H — H1 2023 Earnings Presentation
43 slides from Shanghai Henlius Biotech, Inc. Class H's earnings presentation, August 2023
Slide 1: Henlius (2696.HK) 1H 2023 Results Investor Presentation
Henlius(2696.HK)1H 2023 Results Investor Presentation August 2023 © 2023 Henlius
Slide 2: 1H 2023 Business Highlights & Company Strategy
1H 2023 Business Highlights & 01 Company Strategy © 2023 Henlius
Slide 3: Revenue Tops 2.50B RMB with Net Profit of 240M RMB
Revenue Tops 2.50B RMB with Net Profit of 240M RMB Commercial Operating Revenue BD Pipeline Capacity Cash Flow 2.5B RMB 3 60+ 48KL 0.3B RMB Commercialization Business Development R&D Manufacturing Financial • Achieved sustainable and • HLX10 (HANSIZHUANG) • The latest clinical data of • High utiliza
Slide 4: Our Mission and Vision
Biosimilars Maximize the commercialization value in China and international markets Our Mission and Vision Innovative Drugs Explore new mechanisms, new technology platforms and expand the therapeutic area coverage Affordable Innovation Reliable Quality Globalization Develop towards a biopharma with
Slide 5: Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence
The Sales Growth of Marketed Biosimilars Accelerated; Multiple Pipeline Products Planned for Global Presence • 1H 2023 sales revenue of biosimilars reached ~1.6 billion RMB, 44% YoY growth, exceeding the sales revenue of biosimilars in the full year of 2021 • The biosimilar pipeline covered globally
Slide 6: HANSIZHUANG Entered a New High-growth Stage of Commercialization
HANSIZHUANG Entered into a New High-growth Stage of Commercialization with Differentiated Advantages Differentiated Clinical Differentiated 556M RMB Antibody Advantages Indications • In March 2023, HANSIZHUANG • HANSIZHUANG (Serplulimab) HANSIZHUANG recommended by 9 ES-SCLC (marketed): achieved over
Slide 7: R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs for UMN
R&D for Innovative Drugs: Beyond Oncology, Expanding into New TAs for UMN Product Type & Introduction Innovative Pipeline Distribution by Stage (by Molecule) 32 ✓ Total 63 molecules in pipeline with 49 innovative drugs and 14 biosimilars ✓ Pipeline focuses around oncology while starting to explore n
Slide 8: Expanding Footprints in Global Key Markets with Strategic Alliance Partners
Expanding Footprints in Global Key Markets with Strategic Alliance Partners Europe The US Market Potential in Europe (Million USD) Market Potential in the US (Million USD) HLX02 HLX10 HLX14 HLX11 HLX02 HLX10 HLX14 HLX11 (Trastuzumab) (PD1-L1) (Denosumab) (Pertuzumab) (Trastuzumab) (PD1-L1) (Denosuma
Slide 9: Commercialization
02 Commercialization © 2023 Henlius
Slide 10: HANQUYOU (Trastuzumab): Sales Growth 57% YoY
HANQUYOU (Trastuzumab): Sales Growth 57% YoY International quality Strong growth momentum • First approved trastuzumab biosimilar in China In Billion • First “Chinese nationality” mAb biosimilar approved RMB +57% 1.28B RMB* in Europe 1.28 • BLA under FDA review; expected to be the first “Chinese nat
Slide 11: Excellent Performance of HANQUYOU
Excellent Performance of HANQUYOU Higher sales per capita The only Trastuzumab Fast-growing market Monthly sales over than domestic peers with two specifications share 200M RMB Sales Per Capita1 • 2 specifications were • Achieved ~50% of • Monthly sales over 200M (1H 2023) customized to address HER2
Slide 12: HANSIZHUANG (Serplulimab): First Global PD-1 mAb for SCLC 1L Treatment
HANSIZHUANG (Serplulimab): First Global PD-1 mAb for SCLC 1L Treatment Differentiated strategies to seize the Widespread recognition market • MAA for 1L ES-SCLC indication is under EMA review • Developed differentiated marketing strategies and 556M RMB • Recommended in 2023 CSCO treatment guidelines
Slide 13: HANSIZHUANG Commercialization Highlights
HANSIZHUANG Commercialization Highlights High Market Share Driven by First-class Commercialization Efficiency Differentiation Strategy Outstanding Achievements Differentiation Strategy • Sales outperformed most of the competing PD- 1/PD-L1 since its launch in 2021 Focus on SCLC 556M RMB • Expected t
Slide 14: HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023
HANBEITAI (Bevacizumab): Commercialization Acceleration in 2023 Acceleration on market access Exploration for new medication and penetration methods 45M RMB • Covered by NRDL in 31 provinces, and • The only bevacizumab biosimilars with phase completed tendering and procurement platform Revenue in 1H
Slide 15: HANLIKANG (Rituximab): Strengthen the Market Leader Position
HANLIKANG (Rituximab): Strengthen the Market Leader Position Acceleration on market access Commercialization Progress and penetration • Approved in February 2019 as the first approved • Jiangsu Fosun, a subsidiary of Fosun Pharma, is responsible for HANLIKANG’s commercialization in China 254M RMB •
Slide 16: HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area
HANDAYUAN (Adalimumab): Entered Autoimmune Disease Area Improve patients’ availability and Work with partners to penetrate the accessibility market 21M RMB • • Henlius’ first autoimmune disease product Covered by NRDL in 30 provinces, and completed • Jiangsu Wanbang is responsible for China-region s
Slide 17: Business Development
03 Business Development © 2023 Henlius
Slide 18: HLX10 Out-licensing in the Middle East and North Africa
HLX10 Out-licensing in the Middle East and North Africa US$7M Upfront Payment US$665M in Total* HANSIZHUANG (Serplulimab) Covering 12 countries in PT Kalbe Genexine Biologics the Middle East and North Africa * Included the sales milestones from the previous deal with Kalbe covering Southeast Asia re
Slide 19: Alliance with Strong Partner to Develop Potential FIC Products
Alliance with Strong Partner to Develop Potential FIC Products Win-Win Collaboration Co-develop innovative drugs by the new FBDB™2 platform Innovative Platform Unique biologics with multiple targeting modes Unlock the innate and adaptive immune systems to kill tumors Improve innovative drug R&D meth
Slide 20: Research & Development
04 Research & Development © 2023 Henlius
Slide 21: Product Pipeline
Product Pipeline Pre-clinical IND Phase I Phase II Phase III NDA Marketed HANSIZHUANG (serplulimab)(1) HLX61 HLX6018 HLX51 HLX10(1) (serplulimab)+HLX60(2) HLX10(1)(serplulimab)+HANBEITAI HLX10(1) (serplulimab)+chemo HLX10(1) (serplulimab)+chemo PD-1 Undisclosed (tumor immunity) GARP/TGF-β1 OX40 PD-1
Slide 22: Clinical Pipeline Milestones: 1H 2023 Review
Clinical Pipeline Milestones: 1H 2023 Review 1H2023 HLX10 ES-SCLC1 1L (EU) NDA/BLA/MAA Submission HLX10 HLX07+HLX10 sqNSCLC2 ESCC3 Final OS results 1L, 2L and late-line (PoC) 1L (Pivotal) ‘ Key Clinical Data HLX208 Readouts BRAF V600E LCH/ECD4 - 22pts Innovative mAb Innovative small molecule 1. Exte
Slide 23: Clinical Pipeline Milestones: 2023-2024 (expected)
Clinical Pipeline Milestones: 2023-2024 (expected) 2H2023 2024 HLX10 HLX04-O ES-SCLC2 Wet AMD3 1L (US) 1L (CN) HLX10 nsNSCLC1 HLX11 1L (CN) HLX14 Breast cancer NDA/BLA/MAA Neoadjuvant therapy PMOP4 (EU & US) Submission (US) HLX10 HLX10 HLX07+HLX10 HLX10 HLX208 nsNSCLC nsNSCLC sqNSCLC5 (Stage 3) ES-S
Slide 24: HLX11 and HLX14: Multi-Regional Phase III Clinical Trials Ongoing
HLX11 and HLX14: Multi-Regional Phase III Clinical Trials Ongoing HLX11 – Pertuzumab Biosimilar HLX14 – Denosumab Biosimilar • Focusing on China, the US and Europe, the MRCT1 • As the first China-made Denosumab biosimilar aiming plans to enrol 900 patients globally, expected to be the to be approved
Slide 25: Serplulimab: Targeting Differentiated Indications
Serplulimab: Targeting Differentiated Indications According to the baseline data analysis of 649 subjects in the Checkmate, 60% advanced GC patients had CPS ≥ 5. The trial design had focused on PD-L1-positive patients (CPS ≥ 5) from Gastric Cancer the very beginning. Serplulimab aims to be first per
Slide 26: HLX07: Address Unmet Medical Needs of High EGFR Expression Patients
HLX07: Address Unmet Medical Needs of High EGFR Expression Patients ESCC Study Design (Phase II) HLX07 Indication Profile (Phase II) Inclusion Criteria: Group A (1L) • Age 18-75 years; ECOG PS 0 or 1 HLX07, 1000 mg; Serplulimab, 200 mg; Chemotherapy • ESCC or esophageal adenosquamous carcinoma Q2W I
Slide 27: HLX22: Potential to Change the SOC of 1L GC
HLX22: Potential to Change the SOC of 1L GC HLX22 (HER2) • HLX22 targets at different epitopes within domain IV of Her2 Anti-HER2 mAb • PDx data shows HLX22 & Trastuzumab combo has more advantages than Trastuzumab & Pertuzumab combo in GC • Current SOC of 1L mGC/GJC treatment Trastuzumab + chemo app
Slide 28: R&D: Pre-clinical Assets
4.1 R&D: Pre-clinical Assets © 2023 Henlius
Slide 29: Antibody Drug Conjugate (ADC) R&D Platform: Hanjugator
Antibody Drug Conjugate (ADC) R&D Platform: HanjugatorTM Develop differentiated Increase the efficacy of Improve safety and Enhance the selectivity Expand the application ADC products: ADCs: develop therapeutic window of of ADCs: build Tumor scenarios of ADCs: establish a new Multiple-Payloads ADC A
Slide 30: Innovative Antibody Drug Conjugate (ADC)
Innovative Antibody Drug Conjugate (ADC) HLX42 EGFR ADC HLX43 PD-L1 ADC Molecular Design Molecular Design • HLX42 EGFR ADC utilizes the properties of tumor tissues, and its payload-linker can be • HLX43 PD-L1 ADC utilizes the properties of tumor tissues, and its payload-liker can be specifically rel
Slide 31: 5D Platform Targeting Oncology, Metabolism, Immunity and Neurology
5D Platform Targeting Oncology, Metabolism, Immunity and Neurology Based on the Deep Data Driven Drug Discovery (5D) Driven by the Biocomputing Accelerated Molecule platform, integrate medical informatic data to discover Design (BAMD) platform, design new drug molecules new targets, mechanisms and d
Slide 32: Manufacturing
05 Manufacturing © 2023 Henlius
Slide 33: International Leading Capabilities on Manufacturing and Quality Management
International Leading Capabilities on Manufacturing and Quality Management Xuhui Site Songjiang Songjiang 1st Plant 2nd Plant • Manufacturing capacity optimization: • Increasing supply of HANQUYOU • Plant construction for Phase I & II trials: The scale of commercial GMP batches has (Trastuzumab): Ov
Slide 34: Operation Excellence and Continuous Innovation
Operation Excellence and Continuous Innovation Technical Innovation Lean Operations • Reached key milestone of using Lean • 34 on-going lean operations domestic production consumables Operations projects with ~10M RMB expected and completed commercial scale annualized returns process validation • Th
Slide 35: 1H 2023 Financial Review
06 1H 2023 Financial Review © 2023 Henlius
Slide 36: 1H 2023 Revenue of RMB 2.50 Billion with 93.9% YoY
1H 2023 Revenue of RMB 2.50 Billion with 93.9% YoY Revenue Product Sales 1H 2023 Revenue Breakdown (in Million RMB) (in Million RMB) 1,276.7 1H 23 2,500.5 2,152.8 51.1% 93.9% 1H 22 82.2% 1H 23 Share % 103.5% 812.7 112.5% 1,181.5 22.2% 1,289.4 556.3 10.2% 13.9% 474.0% 480.2% 555.9 347.7 633.6 254.1 2
Slide 37: Achieved Profitability in 1H 2023 with RMB ~330M Operating CF
Achieved Profitability in 1H 2023 with RMB ~330M Operating CF Net profit (net loss) excl. extraordinary items R&D investment (in Million RMB) (in Million RMB) 827 1H 20 1H 21 1H 22 1H 23 674 230 293 (10.0%) 126 (62.6%) 9.2% (129) 534 548 (402.2%) (444) (397) 1H 22 1H 23 Net profit (net loss) excl. e
Slide 38: Financial Highlights
Financial Highlights Financial Data (selected) 1H 23 1H 22 YoY Growth Unit In Million RMB % of revenue In Million RMB % of revenue % Revenue 2,500.5 100.0% 1,289.4 100.0% 93.9% Product sales 2,152.9 86.1% 1,181.6 91.6% 82.2% BD and other revenue 347.6 13.9% 107.8 8.4% 222.4% Cost of sales (721.6) (2
Slide 39: Net Profit: Turned into Profit in 1H 2023
Net Profit: Turned into Profit in 1H 2023 In Thousand RMB +492,075 (195.2%) -23,337 239,980 470,207 -404,312 124,804 -3,171 -13,331 33,836 -7,605 351,803 -252,095 -36,817 Actual HANLIKANG and Contribution Contribution Contribution Net profit Selling and Administrative R&D expenses Government Financi
Slide 40: 2023 Performance Outlook
07 2023 Performance Outlook © 2023 Henlius
Slide 41: Our Goals for 2023
Our Goals for 2023 Revenue: rapid growth driven by promoting clinical advantage of HANSIZHUANG and HANQUYOU Profitability: improve P&L level, and improve profits from internal operation Cashflow: positive OCF generated for the past two years; strengthen organic growth in 2023 and build strong and he
Slide 42: Disclaimer
声明 Disclaimer • 复宏汉霖、陈述人或提供人对本文件内容(文件内容亦有可能包括前瞻性陈述)均不做出明示或默示的保证、声明或陈述(包括但不限于:本内容针对为任意特定目的而关于内容 所具有的及时性、通用性、精确性的声明,或者关于使用本文件内容所获得信息无误可信的声明)。如因有关内容存在错误、遗漏或失准之处而引致的行为或结果,复宏汉霖、陈 述人或提供人对此不承担责任。 • 本文件及其中所包含内容的所有权利包括版权均由复宏汉霖独家所有,其中相关的“Henlius” 和“复宏汉霖”字样、图案及相关LOGO标识均为复宏汉霖合法所有的字号、商标和 标识。未经复宏汉霖书面同意,任何第三方不得以包括
Slide 43: © 2023 Henlius
A | Henlius #22:3V% ARENA Sia Mio Reliable Quality Affordable Innovation
Shanghai Henlius Biotech — H1 2023 Earnings Presentation on 6ix